



Briefing Note update for the Member Forum May 2022

Quality Improvement of Primary malignancy and Metastatic disorder:
update following feedback from members, users, and other stakeholders.

Purpose

To update the Member Forum on the feedback received and collated and changes incorporated into the proposal following circulation to Member Forum, Editorial Advisory Group, Content Managers Advisory Group, and Cancer Synoptic Reporting Group, and chair of the Observable and Investigation Model Project.

Background

See Briefing Note posted to the Member Forum, March 2022, “Primary and metastatic malignancy disorder concepts”.

Update following feedback

- Proposals for remodeling primary malignancy disorders, also involving changes to the morphologic abnormality hierarchy, have been received favorably, without modification.
- Terming change to align all metastatic disorder descriptions, using ‘metastatic’ for the FSN and PT and with ‘secondary’ as a synonym - accepted.
- Proposals for inactivation of 14799000 |Neoplasm, metastatic (morphologic abnormality)| and subtypes; some concerns voiced regarding the loss of the (/6) metastatic morphology concepts.
- For the 704321009 |Characterizes (attribute)|, as used in the observable entity model, the subtypes of target value 1204295007 |Malignant proliferation of neoplasm (qualifier value)| will not be further expanded to include any concept

specifying two processes as feedback has pointed out that this constitutes 'nesting' hence not supported in the current observables model. The 704321009 [Characterizes (attribute)] definition will be clarified under the guidance of the chair of the Observable and Investigation Model Project.

Planned amendment to proposal for metastatic disorders and morphologies

Existing 14799000 [Neoplasm, metastatic (morphologic abnormality)] and subtypes will be retained and used as the target for the 116676008 [Associated morphology (attribute)] for defining metastatic disorders. Additional subtypes of 14799000 [Neoplasm, metastatic (morphologic abnormality)] will be added as required to model metastatic disorders, or if requested by users. The 308489006 [Pathological process (qualifier value)] attribute with value 1505291000004103 [Discontinuous metastatic spread (qualifier value)] will be used as outlined in the Briefing Note to capture the pathologic process that results in the abnormal morphological structure.

This briefing note update will be distributed to selected Advisory and Project Groups. Please contact info@snomed.org with any inquiries.